CBLL (CeriBell) Accounts Payable & Accrued Expense: $10.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CBLL CeriBell Inc CBLL
12 GF Score
Price $24.72
! 5 Warning Signs
View Full Analysis

What is CeriBell Accounts Payable & Accrued Expense?

CeriBell CBLL +0.61% 12 Accounts Payable & Accrued Expense is $10.3 Mil as of Jun. 2026. GuruFocus rates CBLL with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

CeriBell's quarterly accounts payable & accrued expense increased from Dec. 2025 ($10.1 Mil) to Mar. 2026 ($11.8 Mil) but then declined from Mar. 2026 ($11.8 Mil) to Jun. 2026 ($10.3 Mil).

CeriBell's annual accounts payable & accrued expense increased from Dec. 2023 ($5.1 Mil) to Dec. 2024 ($6.8 Mil) and increased from Dec. 2024 ($6.8 Mil) to Dec. 2025 ($10.1 Mil).

CeriBell Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for CeriBell's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CeriBell Accounts Payable & Accrued Expense Chart

CeriBell Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
3.89 5.14 6.80 10.08

CeriBell Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.83 8.02 10.08 11.82 10.31
CBLL
12GF Score
CeriBell Inc CBLL
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CeriBell Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $10.3 Mil mean?
CeriBell (CBLL) has a Accounts Payable & Accrued Expense of $10.3 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on CeriBell and its competitors.
Is CeriBell's Accounts Payable & Accrued Expense too high?
CeriBell's current Accounts Payable & Accrued Expense is $10.3 Mil. Overall, CeriBell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CeriBell's Accounts Payable & Accrued Expense compare to BBNX and SIBN?
CeriBell's Accounts Payable & Accrued Expense of $10.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Medical Devices & Instruments company?
A good Accounts Payable & Accrued Expense depends on the Medical Devices & Instruments industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on CeriBell and its competitors. CeriBell's current Accounts Payable & Accrued Expense is $10.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CeriBell stock overvalued right now?
CeriBell (CBLL) has a current Accounts Payable & Accrued Expense of $10.3 Mil. The current Accounts Payable & Accrued Expense is $10.3 Mil. CeriBell's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For CeriBell (CBLL), the current Accounts Payable & Accrued Expense is $10.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CeriBell Business Description

Other Exchanges W3H:Germany
Address 360 N. Pastoria Avenue, Sunnyvale, CA, USA, 94085
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
12GF Score

Get the complete analysis for CBLL

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.72
Price